Substituted azaindazole compounds
    18.
    发明授权
    Substituted azaindazole compounds 有权
    取代的氮杂咔唑化合物

    公开(公告)号:US09266880B2

    公开(公告)日:2016-02-23

    申请号:US13884676

    申请日:2011-11-09

    IPC分类号: C07D487/04 C07D471/04

    CPC分类号: C07D471/04 C07D487/04

    摘要: Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

    摘要翻译: 公开了式(I)的氮杂咔唑化合物或其药学上可接受的盐,其中:Q为:(i)包含至少一个氮杂原子并被0至2个R g取代的5元杂芳基; 或(ii)选自式(II)的9至10元双环杂芳基; 其中环A是被0至2个R g取代的5至6元芳基或杂芳基稠环; 并且R1,R2,R3和Rg在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法,以及包含这些化合物的药物组合物。